These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 19947815)

  • 1. Pharmacokinetics and pharmacodynamics of liraglutide, a long-acting, potent glucagon-like peptide-1 analog.
    Meece J
    Pharmacotherapy; 2009 Dec; 29(12 Pt 2):33S-42S. PubMed ID: 19947815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiating incretin therapies based on structure, activity, and metabolism: focus on liraglutide.
    Grossman S
    Pharmacotherapy; 2009 Dec; 29(12 Pt 2):25S-32S. PubMed ID: 19947814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide.
    Watson E; Jonker DM; Jacobsen LV; Ingwersen SH
    J Clin Pharmacol; 2010 Aug; 50(8):886-94. PubMed ID: 20133507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
    Gallwitz B
    Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
    Moon HS; Kim MK; Son MH
    Arch Pharm Res; 2011 Jul; 34(7):1041-3. PubMed ID: 21811909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of the pharmacokinetics, efficacy and safety of liraglutide.
    Bode B
    Diabetes Res Clin Pract; 2012 Jul; 97(1):27-42. PubMed ID: 22245694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
    Ryan GJ; Hardy Y
    J Clin Pharm Ther; 2011 Jun; 36(3):260-74. PubMed ID: 21545609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the use of liraglutide for glycemic control in healthy and Type 1 diabetes mellitus suffering dogs.
    Oda H; Mori A; Lee P; Saeki K; Ishioka K; Arai T; Sako T
    Res Vet Sci; 2013 Oct; 95(2):381-8. PubMed ID: 23632200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].
    Reboldi G
    G Ital Cardiol (Rome); 2009 Jul; 10(7):434-47. PubMed ID: 19761101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
    Flint A; Kapitza C; Hindsberger C; Zdravkovic M
    Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
    Nauck MA; Meier JJ
    Regul Pept; 2005 Jun; 128(2):135-48. PubMed ID: 15780433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next-generation GLP-1 therapy: an introduction to liraglutide.
    Repas T
    Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liraglutide: a review of the first once-daily GLP-1 receptor agonist.
    Bode B
    Am J Manag Care; 2011 Mar; 17(2 Suppl):S59-70. PubMed ID: 21517658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus.
    Drab SR
    Pharmacotherapy; 2009 Dec; 29(12 Pt 2):43S-54S. PubMed ID: 19947816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction.
    Morrow L; Hompesch M; Guthrie H; Chang D; Chatterjee DJ
    Diabetes Obes Metab; 2011 Jan; 13(1):75-80. PubMed ID: 21114606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes.
    Davies MJ; Kela R; Khunti K
    Diabetes Obes Metab; 2011 Mar; 13(3):207-20. PubMed ID: 21205109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.